SAHMRI heart disease trial seeking patients in effort to reduce hospitalisation
Health & Medical
SAHMRI is seeking 590 patients suffering heart disease as part of a major, region-first trial and evaluation of treatment methods for those suffering atrial fibrillation.
Sign up to receive notifications about new stories in this category.
Thank you for subscribing to story notifications.
The University of Adelaide’s Chair of Cardiology Research, Professor Prash Sanders, is the lead investigator of the CAAN-AF trial and responsible for approximately 35 sites at major cardiac centres around Australia and New Zealand.
“The combination of heart failure and atrial fibrillation presents considerable challenges in our day to day clinical practice. The results of this study will have global implications,” Professor Sanders said.
Thousands of Australians are affected by heart failure and the associated condition of atrial fibrillation, a type of arrhythmia that causes over 30,000 hospitalisations in Australia per year.
The trial is a major collaboration between Australia and New Zealand, and is expected to result in real changes to clinical practice and guidelines.
Patients who believe that they are eligible for the trial are encouraged to discuss their cardiologist. For further information please contact: Professor Prash Sanders on (08) 8222 2723 or visit the SAHMRI website at www.sahmri.com.
Jump to next article